SCHEMBL1872941

SCHEMBL1872941

OC[C@H]1CCCCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL94571 1.00
SCHEMBL703052 1.00
Hydrochloric Acid SCHEMBL2011967 0.97
SCHEMBL31048379 0.97
Hydrochloric Acid SCHEMBL4328612 0.97
SCHEMBL5482526 0.97
Hydrochloric Acid SCHEMBL2011971 0.97
Bromide SCHEMBL11156909 0.97
SCHEMBL31350235 0.97 CYP2D6 (0.52)
Hydrochloric Acid SCHEMBL31323394 0.95 KMT2A (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105873588-A Compounds for the treatment of cancer and uses thereof 戈里奥诺瓦公司 2016-08-17 CN claimed
US-20260103454-A1 MODULATORS OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS INC (US) 2026-04-16 US disclosed
US-20260078135-A1 POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 ENLIVEN INC (US) 2026-03-19 US disclosed
EP-3806853-B1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES ONCO3R THERAPEUTICS BV (BE) 2026-03-18 EP disclosed
US-20250289813-A1 CDK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS ONQUALITY PHARMACEUTICALS CHINA LTD. (CN) 2025-09-18 US disclosed
EP-4587124-A1 POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 Enliven Inc. (US) 2025-07-23 EP disclosed
US-20250163038-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. 2025-05-22 US disclosed
EP-4547676-A1 CYCLIC BORONIC ESTERS AND THEIR USES Principia Biopharma Inc. (US) 2025-05-07 EP disclosed
EP-4514796-A1 CDK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS OnQuality Pharmaceuticals China Ltd. (CN) 2025-03-05 EP disclosed
WO-2025029075-A1 NOVEL BIPHENYL DERIVATIVE AS PD-L1 INHIBITOR (주)아이랩 2025-02-06 WO disclosed
WO-2002100865-A1 BENZOXAZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS AKZO NOBEL N.V. (NL) 2002-12-19 WO disclosed
US-20020099047-A1 Oxazepine derivatives and medicine containing the same AJINOMOTO CO., INC. (JP) 2002-07-25 US disclosed
EP-1142884-A1 OXAZEPINE DERIVATIVES AND DRUGS CONTAINING THE SAME Ajinomoto Co., Inc. (JP) 2001-10-10 EP disclosed
EP-1108053-A1 METHOD FOR PREPARING (2R)-PIPERIDINE DERIVATIVES LONZA A.G. (CH) 2001-06-20 EP disclosed
US-6080859-A 1-CHLOROMETHYL, 3-((HETEROARYL OR ARYL)CARBONYL), 5-(HETEROCYCLE-AMINOCARBONYLOXY),7-TRIFLUOROMETHYL, 8-ALKOXYCARBONYL-1,2,3,6-TETRAHYDROPYRROLO(3,2-E)INDOLE OF GIVEN STRUCTURE; ANTITUMOR AND ANTIMICROBIAL ACTIVITY KYORIN PHARMACEUTICAL CO., LTD. (JP) 2000-06-27 US disclosed
WO-2000012745-A1 METHOD FOR PREPARING (2R)-PIPERIDINE DERIVATIVES LONZA AG (CH) 2000-03-09 WO disclosed
EP-0972775-A1 PYRROLOINDOLE DERIVATIVES AND INTERMEDIATES IN PRODUCING THE SAME KYORIN PHARMACEUTICAL CO., LTD. (JP) 2000-01-19 EP disclosed
EP-0815103-A1 TRYPSIN AND THROMBIN INHIBITORS Novartis AG (CH) 1998-01-07 EP disclosed
WO-1996029327-A1 TRYPSIN AND THROMBIN INHIBITORS NOVARTIS AG (CH) 1996-09-26 WO disclosed
US-5130432-A Process for preparing cyclic amines and intermediate products thereof SYNTEX (U.S.A.) INC. (US) 1992-07-14 US disclosed